共 20 条
Risk Factors and Outcomes of Ganciclovir-Resistant Cytomegalovirus Infection in Solid Organ Transplant Recipients
被引:104
作者:
Fisher, Cynthia E.
[1
,2
]
Knudsen, Janine L.
[1
]
Lease, Erika D.
[1
,3
]
Jerome, Keith R.
[2
,4
]
Rakita, Robert M.
[1
]
Boeckh, Michael
[1
,2
]
Limaye, Ajit P.
[1
]
机构:
[1] Univ Washington, Div Allergy & Infect Dis, Seattle, WA 98195 USA
[2] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, 1124 Columbia St, Seattle, WA 98104 USA
[3] Univ Washington, Div Pulm & Crit Care, Seattle, WA 98195 USA
[4] Univ Washington, Dept Lab Med, Virol Div, Seattle, WA 98195 USA
基金:
美国国家卫生研究院;
关键词:
cytomegalovirus;
solid organ transplant;
ganciclovir resistance;
risk factors;
outcomes;
RAPID DETECTION;
DISEASE;
EMERGENCE;
PROPHYLAXIS;
FOSCARNET;
SAMPLES;
IMPACT;
UL97;
ERA;
D O I:
10.1093/cid/cix259
中图分类号:
R392 [医学免疫学];
Q939.91 [免疫学];
学科分类号:
100102 ;
摘要:
Background. Ganciclovir-resistant (ganR) cytomegalovirus (CMV) is an emerging and important problem in solid organ transplant (SOT) recipients. Only through direct comparison of ganR- and ganciclovir-sensitive (ganS) CMV infection can risk factors and outcomes attributable specifically to ganciclovir resistance appropriately be determined. Methods. We performed a retrospective, case-control (1: 3) study of SOT recipients with genotypically confirmed ganR-CMV (n = 37) and ganS-CMV infection (n = 109), matched by donor/recipient CMV serostatus, year and organ transplanted, and clinical manifestation. We used chi(2) (categorical) and Mann-Whitney (continuous) tests to determine predisposing factors and morbidity attributable to resistance, and Kaplan-Meier plots to analyze survival differences. Results. The rate of ganR-CMV was 1% (37/3467) overall and 4.1% (32/777) among CMV donor-positive, recipient-negative patients, and was stable over the study period. GanR-CMV was associated with increased prior exposure to ganciclovir (median, 153 vs 91 days, P<.001). Eighteen percent (3/17) of lung transplant recipients with ganR-CMV had received <6 weeks of prior ganciclovir (current guideline-recommended resistance testing threshold), and all non-lung recipients had received = 90 days (median, 160 [range, 90-284 days]) prior to diagnosis of ganR-CMV. GanR-CMV was associated with higher mortality (11% vs 1%, P = .004), fewer days alive and nonhospitalized (73 vs 81, P = .039), and decreased renal function (42% vs 19%, P = .008) by 3 months after diagnosis. Conclusions. GanR-CMV is associated with longer prior antiviral duration and higher attributable morbidity and mortality than ganS-CMV. Upcoming revised CMV guidelines should incorporate organ transplant-specific thresholds of prior drug exposure to guide rational ganR-CMV testing in SOT recipients. Improved strategies for prevention and treatment of ganR-CMV are warranted.
引用
收藏
页码:57 / 63
页数:7
相关论文